期刊
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY
卷 28, 期 4, 页码 223-229出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/GCO.0000000000000278
关键词
fertility preservation; gonadotropin-releasing hormone agonist; gonadotoxicity; pregnancies after chemotherapy; premature ovarian failure
Purpose of review Fertility preservation has recently gained a worldwide interest among fertility specialists, oncologists, and all healthcare providers. Thus, the protection against iatrogenic infertility caused by chemotherapy assumes a high priority. Specifically, the issue of endocrine prevention of gonadotoxicity is still a controversial subject. Recent findings During the last year, many publications on this subject appeared, swinging the pendulum toward the beneficial role of gonadotropin-releasing hormone agonist (GnRHa) cotreatment for fertility preservation despite gonadotoxic chemotherapy. Here, we summarize the recent publications on fertility preservation and minimizing chemotherapy-induced gonadotoxicity. Summary More than 10 recent meta-analyses have concluded that GnRHa is beneficial and may decrease the risk of premature ovarian failure and increase the pregnancy rate in survivors. Furthermore, two recent international meetings of experts have concluded that GnRHa is effective and should be offered to every young woman facing gonadotoxic chemotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据